AveXis files for $115M IPO

Gene therapy company AveXis Inc. (Chicago, Ill.) filed to raise up to $115 million in an IPO on NASDAQ underwritten by Goldman Sachs, Jefferies, BMO Capital Markets and Chardan. In 1H17, AveXis hopes to begin pivotal studies in the U.S. and EU of AVXS-101 to treat spinal muscular atrophy (SMA) type 1. The therapy, which uses RegenxBio's NAV rAAV9 vector technology to deliver the survival motor neuron ( SMN) gene, has Orphan Drug designation from FDA to treat all types of SMA, and Fast Track designation to treat SMA type 1. ...